Abstract:While medicinal inorganic chemistry has been practised for over 5000 years, it was not until the late 1800s when Alfred Werner published his ground-breaking research on coordination chemistry that we began to truly understand the nature of the coordination bond and the structures and stereochemistries of metal complexes. We can now readily manipulate and fine-tune their properties. This had led to a multitude of complexes with wide-ranging biomedical applications. This review will focus on the use and potential of metal complexes as important therapeutic agents for the treatment of cancer. With major advances in technologies and a deeper understanding of the human genome, we are now in a strong position to more fully understand carcinogenesis at a molecular level. We can now also rationally design and develop drug molecules that can either selectively enhance or disrupt key biological processes and, in doing so, optimize their therapeutic potential. This has heralded a new era in drug design in which we are moving from a single- toward a multitargeted approach. This approach lies at the very heart of medicinal inorganic chemistry. In this review, we have endeavored to showcase how a "multitargeted" approach to drug design has led to new families of metallodrugs which may not only reduce systemic toxicities associated with modern day chemotherapeutics but also address resistance issues that are plaguing many chemotherapeutic regimens. We have focused our attention on metallodrugs incorporating platinum and ruthenium ions given that complexes containing these metal ions are already in clinical use or have advanced to clinical trials as anticancer agents. The "multitargeted" complexes described herein not only target DNA but also contain either vectors to enable them to target cancer cells selectively and/or moieties that target enzymes, peptides, and intracellular proteins. Multitargeted complexes which have been designed to target the mitochondria or complexes inspired by natural product activity are also described. A summary of advances in this field over the past decade or so will be provided.

Rhenium‐Based Complexes and in Vivo Testing: A Brief History

Rhenium‐Based Complexes and in Vivo Testing: A Brief History

From Concept to Cure: The Road Ahead for Ruthenium‐Based Anticancer Drugs

Designing Ruthenium Anticancer Drugs: What Have We Learnt from the Key Drug Candidates?

Ruthenium Complexes as Anticancer Agents: A Brief History and Perspectives

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.

Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?

Dinuclear Rhenium(I) Tricarbonyl Complexes as Anticancer Drug Candidates

Recent Advances in Ruthenium and Platinum Based Supramolecular Coordination Complexes for Antitumor Therapy

Metal-based Anticancer Chemotherapeutic Agents.

Ruthenium-based Antitumor Drugs and Delivery Systems from Monotherapy to Combination Therapy

A review on metal complexes and its anti-cancer activities: Recent updates from in vivo studies

Homo and heterometallic ruthenium and platinum complexes with multiple targets for therapeutic applications: a review

Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics

Anticancer and Antibiotic Rhenium Tri- and Dicarbonyl Complexes: Current Research and Future Perspectives

Metal Complexes with Aromatic N-Containing Ligands As Potential Agents in Cancer Treatment

Recent trends in the design and delivery strategies of ruthenium complexes for breast cancer therapy

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Metallo-Drugs in Cancer Therapy: Past, Present and Future

Functionalization and Cancer-Targeting Design of Ruthenium Complexes for Precise Cancer Therapy.